On December 12, 2014, the U. S. Food and Drug Administration approved ramucirumab (Cyramza Injection, Eli Lilly and Company) for use in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression...
The U.S. Food and Drug Administration today approved a new use for Jakafi (ruxolitinib) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Jakafi is the first drug approved by the FDA for this condition.
On December 3, 2014, the U. S. Food and Drug Administration granted accelerated approval for blinatumomab (BLINCYTO, Amgen Inc.) for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (R/R ALL).
Thursday & Friday, February 5-6 2015 Hilton Austin, 1-800-584-5091, Airport 9515 Hotel Drive, Austin, Texas 78719 Regular Room: Single/Double $145.00 Members Register Here Brochure with Agenda CHOP February 2015 Invitation Exhibitors MUST Register at:...
Dear Healthcare Provider, As you might know, the Genentech® Access to Care Foundation (GATCF) recently changed its eligibility criteria. The changes to the criteria were recently communicated to your practice via a letter from GATCF, but I wanted to ensure you...
